Block Organ Transplant Purchases from China Act of 2025

Bill Number

H.R. 2114

Origin Chamber

House

Congress

119th Congress, Session 1

Policy Area

Health

Status

Introduced

Latest Action

2025-03-14: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Last Updated

2025-05-14T08:05:37Z

AI-Generated Summary

Purpose of the Legislation

The "Block Organ Transplant Purchases from China Act of 2025" (H.R. 2114) aims to prevent the use of U.S. federal health programs, private insurance, and health care services for organ transplants linked to the People's Republic of China. It seeks to address concerns about organ procurement practices by prohibiting coverage and services for such transplants starting January 1, 2026, while allowing exceptions for life-saving follow-up care.

Key Provisions

• Medicare Amendments (Social Security Act, Title XVIII): Bars payment for "prohibited organ transplants" or related items/services (e.g., follow-up visits, tests, drugs) after January 1, 2026, unless they are needed to save a patient's life post-transplant.
• Medicaid Amendments (Social Security Act, Title XIX): Prohibits state Medicaid plans from covering prohibited transplants or connected services after January 1, 2026, with similar life-saving exceptions. Includes conforming changes to ensure enforcement in managed care settings.
• Private Insurance Restrictions (Public Health Service Act, Title XXVII): Requires group health plans and health insurance issuers to exclude coverage for prohibited transplants or related services, effective for plan years starting January 1, 2026, with life-saving exceptions.
• National Organ Transplant Act Additions:
• Defines a "prohibited organ transplant" as one occurring in China or involving organs not sourced through the Organ Procurement and Transplantation Network (OPTN), a U.S. system for coordinating organ donations.
• Bans health care providers from performing or providing services for such transplants after January 1, 2026.
• Imposes penalties: Criminal (fines and up to 2 years imprisonment for knowing violations under U.S. criminal code); Civil (three times the cost of the transplant/service, enforced by the U.S. Attorney General or state attorneys general, with federal intervention allowed).
• Covers "specified human organs" including kidneys, livers, hearts, lungs, pancreases, bone marrow, corneas, eyes, bones, intestines, and vascularized composite allografts (tissue grafts with blood supply, like hands or faces), plus fetal parts.
• Rulemaking Requirement: The Secretary of Health and Human Services (HHS) must issue rules by January 1, 2026, to identify prohibited items/services and calculate costs for civil penalties.

Significant Changes to Existing Law

• Introduces the first federal ban on transplants specifically tied to a foreign country (China), expanding beyond general U.S. laws on organ trafficking and procurement.
• Adds new definitions for "prohibited organ transplant" and "specified human organ" to the National Organ Transplant Act, which previously focused on domestic ethical standards without geographic restrictions.
• Creates novel penalties (criminal and civil) for health care providers involved in China-linked transplants, shifting from voluntary compliance to mandatory enforcement.
• Conditions federal funding (Medicare/Medicaid) and private insurance on U.S.-sourced organs via OPTN, altering reimbursement rules that previously did not exclude foreign organs outright.

Potential Impacts

• Government Agencies: HHS and the Centers for Medicare & Medicaid Services (CMS) will face increased administrative burdens for rulemaking, enforcement, and cost calculations. State Medicaid programs must update plans, potentially straining budgets. The Department of Justice may handle more civil/criminal cases.
• Citizens: U.S. patients needing transplants may lose insurance coverage for China-sourced options, limiting access and raising out-of-pocket costs. This could affect vulnerable groups reliant on Medicare/Medicaid, though life-saving care remains covered. It promotes reliance on domestic organ supplies, which are already limited.
• International Relations: May heighten U.S.-China tensions by implicitly criticizing China's organ practices (e.g., alleged unethical sourcing), potentially affecting broader diplomatic or trade ties in health sectors without direct economic sanctions.

Main Stakeholders Affected

• Healthcare Providers: Hospitals, transplant centers, and doctors cannot perform or support prohibited transplants without facing fines or jail time; must verify organ sources.
• Patients and Recipients: Individuals awaiting organs (e.g., those with kidney failure or heart disease) may face delays or barriers if seeking foreign options, impacting transplant waitlists.
• Insurers and Health Plans: Private companies and group plans must revise policies to exclude coverage, increasing compliance costs.
• Organ Procurement Organizations: OPTN and similar groups benefit from mandated U.S. sourcing, potentially boosting domestic donations but highlighting supply shortages.
• Federal and State Governments: Bear enforcement roles, with states handling Medicaid adjustments and attorneys general pursuing penalties.
• International Actors: Chinese medical entities indirectly affected by reduced U.S. demand for their organs/transplants.

Notable Legal, Constitutional, or Political Implications

• Legal: Strengthens enforcement of ethical organ sourcing under U.S. law by tying it to federal funding and penalties; civil actions use a "preponderance of evidence" standard (more likely than not), easing proof burdens compared to criminal cases. Defines "health care provider" broadly per existing Social Security Act terms.
• Constitutional: Relies on Congress's authority over interstate commerce and spending (e.g., conditioning Medicare/Medicaid funds), but could face challenges if seen as infringing on patients' rights to medical choice or providers' practice freedoms. No direct free speech or due process issues apparent.
• Political: Signals U.S. concerns over human rights in China's organ system (e.g., potential forced harvesting), aligning with bipartisan foreign policy trends without explicit sanctions. May influence future legislation on global health ethics, though it risks politicizing medical decisions.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Rep. Dunn, Neal P. [R-FL-2]

Cosponsors (3)

Rep. Bilirakis, Gus M. [R-FL-12], Rep. Moolenaar, John R. [R-MI-2], Rep. Hinson, Ashley [R-IA-2]

Recent Actions

• 2025-03-14: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
• 2025-03-14: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
• 2025-03-14: Introduced in House
• 2025-03-14: Introduced in House

Bill Versions

• Block Organ Transplant Purchases from China Act of 2025 — issued 2025-03-14 — PDF (8 pages)